Also, with entry of this amendment, claim 31 has been amended, and new claims 34-44 have been added. Claim 31 has been amended to improve clarity. New claims 34-40 depend from claim 31 and incorporate elements from original claims 4-6 and 9-12, respectively. New independent claim 41 parallels claim 31 but recite a mesh size of greater than about 40 mesh. The original claim 25 provides additional support for claim 41. New claims 42-44 depend from claim 41 and respectively recite elements from original claims 26, 29, and 30. Additional support for these new claims is provided throughout the specification.

Applicants further note that the claim amendment and addition of new claims have been made to improve clarity of claim language and to more clearly point out and distinctly claim Applicant's invention. No new matter has been introduced by the preliminary amendment.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400 x 5209.

Respectfully submitted,

Hugh Wang
Reg. No. 47,163

Appendix Marked-up version of all pending claims

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Telephone: (650) 326-2400
Facsimile: (650) 326-2422
PA 3176447 v1

Marked-up Version of All Pending Claims

31. (Amended) A composition adapted to induce an immune response comprising **an enteric coating and** an immunogen **[contained on]** **bound to** an inert particle **[and having an enteric coating]**, said inert particle having a mesh size greater than **[about]** 35 mesh.

32. (As originally filed) The composition of claim 31 contained in a gel capsule.

33. (As originally filed) The composition of claim 31 further comprising a potentiating agent.

34. (New) The composition of claim 31 wherein said immunogen is selected from the group consisting of a peptide, a protein fragment, a protein, a gene, a gene fragment, a DNA, an RNA and combinations thereof.

35. (New) The composition of claim 31 wherein said immunogen is a vaccine.

36. (New) The composition of claim 33, wherein the potentiating agent is bound to the inert particle, and the inert particle is selected from the group consisting of an immunogen-bound inert particle and a non-immunogen bound inert particle.

37. (New) The composition of claim 31 which induces an increase in the number of T lymphocytes.

38. (New) The composition of claim 37 which induces an increase in a cell population selected from the group consisting of a TH1 lymphocyte, a cytotoxic T lymphocyte (CTL), and combinations thereof.

39. (New) The composition of claim 31 wherein said inert particle has a mesh size greater than about 40 mesh.

40. (New) The composition of claim 31 where said immunogen is bound to an inert particle selected from the group consisting of a nonpareil, a silica powder, a salt crystal and a sugar crystal.

41. (New) A composition adapted to induce an immune response comprising an enteric coating and an immunogen bound to an inert particle, said inert particle having a mesh size greater than about 40 mesh.

42. (New) The composition of claim 41 further comprising a potentiating agent bound to an inert particle, wherein the inert particle is selected from the group consisting of an immunogen-bound inert particle and a non-immunogen bound inert particle.

43. (New) The composition of claim 41 wherein the immune response comprises an increase in a T lymphocyte population.

44. (New) The composition of claim 43 wherein the immune response comprises an increase in a cell population selected from the group consisting of a TH1 lymphocyte, a cytotoxic T lymphocyte (CTL), and combinations thereof.